Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
2.250
-0.050 (-2.17%)
At close: Mar 31, 2025, 4:00 PM
2.217
-0.033 (-1.47%)
After-hours: Mar 31, 2025, 4:22 PM EDT
Mereo BioPharma Group Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Mereo BioPharma Group stock have an average target of 7.71, with a low estimate of 7.00 and a high estimate of 10. The average target predicts an increase of 242.67% from the current stock price of 2.25.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Mereo BioPharma Group stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 4 | 4 | 4 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Initiates $7 | Buy | Initiates | $7 | +211.11% | Mar 27, 2025 |
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +211.11% | Mar 26, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $7 | Buy | Reiterates | $7 | +211.11% | Mar 18, 2025 |
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +211.11% | Jan 13, 2025 |
| LifeSci Capital | LifeSci Capital | Buy Initiates $10 | Buy | Initiates | $10 | +344.44% | Dec 24, 2024 |
Financial Forecast
Revenue This Year
21.76M
Revenue Next Year
36.79M
from 21.76M
Increased by 69.09%
EPS This Year
-0.17
from -0.30
EPS Next Year
-0.03
from -0.17
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 101.0M | 63.8M | 139.7M | ||
| Avg | 21.8M | 36.8M | 77.2M | ||
| Low | n/a | 1.0M | 23.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 193.4% | 279.9% | ||
| Avg | - | 69.1% | 109.8% | ||
| Low | - | -95.3% | -35.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.09 | - | 0.05 | ||
| Avg | -0.17 | -0.03 | -0.02 | ||
| Low | -0.76 | -0.06 | -0.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.